The chemical class known as MIRAB13 Inhibitors includes compounds that have the potential to modulate the function of MIRAB13. This approach is based on indirect modulation, considering that direct inhibitors for MIRAB13 might not be well-defined. The necessity for this indirect approach stems from the multifaceted nature of MIRAB13, a protein involved in various cellular pathways and processes, which lacks a traditional active site suitable for direct ligand binding.
In modulating MIRAB13, these compounds target a range of cellular mechanisms. Given MIRAB13's potential involvement in cellular signaling, endocytic trafficking, and possibly interactions with components of the cytoskeleton, the compounds aim at influencing these specific pathways. By modulating signaling cascades, these compounds can indirectly impact MIRAB13's activity and its role in coordinating cellular functions. For instance, compounds affecting pathways in which MIRAB13 is implicated can lead to changes in the signaling environment, thereby modulating the protein's activity. Additionally, compounds affecting cytoskeletal dynamics and vesicle trafficking can also influence MIRAB13's function. Given the role of the cytoskeleton in maintaining cell shape and enabling various cellular movements, compounds that disrupt this structure can have implications for MIRAB13's activities related to cell morphology and motility. Similarly, compounds that influence vesicle trafficking can affect MIRAB13's role in cellular logistics and communication, particularly in processes involving the internalization and transport of substances within the cell. This approach to modulating MIRAB13's function highlights the importance of understanding the broader cellular context and the network of interactions in which MIRAB13 operates. The development of compounds that can potentially influence MIRAB13 underscores the need for a nuanced understanding of its role within the complex web of cellular interactions and processes. Exploring the potential of these compounds is part of ongoing research strategies aimed at elucidating the functional roles of MIRAB13 and investigating ways to influence its activity in various cellular contexts. The ability of these compounds to modulate MIRAB13's function also emphasizes the complexity of targeting multifunctional proteins and the intricate balance required in manipulating their activity.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Dynamin Inhibitor I, Dynasore | 304448-55-3 | sc-202592 | 10 mg | $89.00 | 44 | |
Could possibly inhibit MIRAB13 by disrupting clathrin-mediated endocytosis, affecting MIRAB13's role in vesicle trafficking. | ||||||
Cytochalasin D | 22144-77-0 | sc-201442 sc-201442A | 1 mg 5 mg | $165.00 $486.00 | 64 | |
Could possibly inhibit MIRAB13 by disrupting actin polymerization, affecting the actin cytoskeleton and MIRAB13's role in cytoskeletal organization. | ||||||
Latrunculin A, Latrunculia magnifica | 76343-93-6 | sc-202691 sc-202691B | 100 µg 500 µg | $265.00 $815.00 | 36 | |
Could possibly inhibit MIRAB13 by altering the dynamics of actin filaments, impacting MIRAB13's function in actin regulation. | ||||||
NSC 23766 | 733767-34-5 | sc-204823 sc-204823A | 10 mg 50 mg | $151.00 $609.00 | 75 | |
Could possibly inhibit MIRAB13 by modulating the Rac1 pathway, affecting actin cytoskeletal organization and potentially MIRAB13's role in cell morphology and motility. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Could possibly inhibit MIRAB13 by modulating the ROCK pathway, influencing actin cytoskeleton organization and cell motility, potentially impacting MIRAB13's role in these processes. | ||||||
(S)-(−)-Blebbistatin | 856925-71-8 | sc-204253 sc-204253A sc-204253B sc-204253C | 1 mg 5 mg 10 mg 25 mg | $72.00 $265.00 $495.00 $968.00 | ||
Could possibly inhibit MIRAB13 by modulating myosin II activity, affecting cell motility and cytoskeletal organization, potentially influencing MIRAB13's function. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Could possibly inhibit MIRAB13 by modulating the PI3K pathway, affecting multiple signaling pathways and potentially impacting MIRAB13's role in vesicle trafficking and signaling. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
Could possibly inhibit MIRAB13 by altering phosphoinositide signaling via the PI3K pathway, potentially influencing MIRAB13's activities in membrane trafficking. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Could possibly inhibit MIRAB13 by modulating the ADP-ribosylation factor (Arf) pathway, disrupting Golgi apparatus function and vesicle trafficking, potentially affecting MIRAB13's role. | ||||||
CK 666 | 442633-00-3 | sc-361151 sc-361151A | 10 mg 50 mg | $321.00 $1040.00 | 5 | |
Could possibly inhibit MIRAB13 by disrupting actin polymerization via the Arp2/3 complex, potentially affecting MIRAB13's role in actin cytoskeleton regulation. | ||||||